FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221046868> ?p ?o ?g. }

• W4221046868 endingPage "139" @default.
• W4221046868 startingPage "137" @default.
• W4221046868 abstract "To the editor, The ongoing COVID-19 pandemic continues to be a global threat. Up to 10% of patients initially presenting with mild illness eventually progress to a severe disease, most of them have a least one comorbid condition [[1]Docherty A.B. et al.Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterization protocol: prospective observational cohort study.BMJ. 2020; 369: m1985Google Scholar]. REGEN-COV, a combination of 2 neutralizing monoclonal antibodies, Casirivimab and Imdevimab has been shown to reduce the viral load, shorten the symptoms duration, reduce the need for hospitalization and the risk of death in high-risk non-hospitalized patients [[2]Weinreich D.M. Sivapalasingam S. Norton T. et al.REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19.N Engl J Med. 2021; 384: 238-251Google Scholar]. Delta variant became a variant of concern by WHO on May 11, 2021 [[3]He X. He C. Hong W. Zhang K. Wei X. The challenges of COVID-19 Delta variant: Prevention and vaccine development.MedComm. 2020; 2 ([published online ahead of print, 2021 Oct 19]) (2021): 846-854https://doi.org/10.1002/mco2.95Google Scholar], but there are only sparse data [[4]Bierle D.M. Ganesh R. Tulledge-Scheitel S. et al.Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities.J Infect Dis. 2021; ([published online ahead of print, 2021 Nov 16]): jiab570https://doi.org/10.1093/infdis/jiab570Google Scholar] on Casirivimab / Imdevimab therapy clinical benefit against the Delta variant and specifically with respect to its effect among vaccinated patients [[4]Bierle D.M. Ganesh R. Tulledge-Scheitel S. et al.Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities.J Infect Dis. 2021; ([published online ahead of print, 2021 Nov 16]): jiab570https://doi.org/10.1093/infdis/jiab570Google Scholar]. Bierle et al [[4]Bierle D.M. Ganesh R. Tulledge-Scheitel S. et al.Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities.J Infect Dis. 2021; ([published online ahead of print, 2021 Nov 16]): jiab570https://doi.org/10.1093/infdis/jiab570Google Scholar]. found monoclonal antibody treatment to be associated with reduced hospitalization in vaccinated high-risk persons with mild-to moderate COVID-19. However, their study was not focused on the Delta variant. We aimed to assess the real-life contribution of Casirivimab/Imdevimab therapy in preventing severe disease outcome, defined as either room air saturation <93% within 14 days of initial presentation or 45-day all-cause mortality [[5]Horby P.W. Mafham M. Peto L. et al.Recovery Collaborative GroupCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.medRxiv. 2021; (06.15)21258542Google Scholar], in high-risk patients with SARS-CoV-2 Delta variant infection, and to compare that effect between vaccinated and unvaccinated patients. After receiving an approval from the institutional research ethics board, we conducted a retrospective cohort study at the emergency department (ED) of a tertiary university-affiliated medical center between June 1, 2021 and September 31, 2021. Included were all patients who presented with a positive PCR for SARS-CoV-2 to the ED or were identified as being positive while hospitalized for a non-COVID-19 indication. All of the study participants fulfilled the criteria for receiving Casirivimab/Imdevimab treatment, based upon the FDA (EUA) guidelines [[6]An EUA for bamlanivimab-a monoclonal antibody for COVID-19.JAMA. 2021; 325: 880-881Google Scholar]:1A positive PCR for SAR-COV-2 within 10 days of presentation.2High-risk factors for developing severe COVID-19 infection, defined as one of the following criteria (16): age >65 years, age >55 years with a chronic heart condition (including ischemic heart disease, chronic dysrhythmias, heart failure, and valves and structural illness) or a pulmonary disease (defined as chronic obstructive pulmonary disease or heavy smoking over 10 pack years), and older than 12 years of age with any of the following: diabetes mellitus, chronic kidney disease, morbid obesity (defined as body mass index ≥35), being severely immunocompromised (organ transplant patients, bone marrow transplant patients, hematologic malignancy, patients receiving anti-CD20 or Fingolimod, congenital immunodeficiency and acquired immunodeficiency, including HIV with a CD4 count <300), pregnancy patients and those with liver failure. Patients who were diagnosed with severe COVID-19 infection already at initial presentation (room air saturation <93%) were excluded. Age, sex, medical history, immunization status (vaccinated patients were defined as those who received at least 2 doses of the BNT162b2 vaccine), Covid-19 related details, vital signs, physical examination, abnormal chest x ray findings (defined as consolidation, ground glass opacities, or nodules, and severe findings defined as those occupying >50% of the lung field) laboratory results, including SARS-CoV-2 IgG antibodies titers (in U/ml), treatment, including Casirivimab/Imdevimab administration as well as implementation of an O2 cannula, non-invasive high flow respiratory support system, or an invasive ventilation and disposition were extracted. Therapy consisted of a single parenteral injection of 1200 mg Casirivimab and 1200 mg Imdevimab. Patient selection was based upon the clinical decision of both the ED physician and the infection disease specialist, and with the patient's agreement. The study is reported according to the STROBE guideline. Data entry and analysis were performed with SPSS Statistics, version 26 (SPSS Inc, Chicago, IL). A P-value <0.05 was considered statistically significant. Three-hundred and fifty-nine patients (189 females, 52.6%) were included in the final cohort, with a median age of 63 years (IQR 41.0-75.0), of them, 116 were treated with Casirivimab/Imdevimab (“cases”) and 243 were not (“controls”). Two-hundred and three patients (56.5%) received at least 2 doses of COVID-19 vaccine and 57 of them were vaccinated with a 3rd dose. Significantly more patients in the treatment group had a severe outcome (20.7% vs. 10.7%, P = 0.01). The patients who were treated with Casirivimab/Imdevimab, compared to those who were not, were significantly older (62.2 ± 18.3 years vs. 57.6 ± 22.2 years, P = 0.03), had higher rates of immunosuppressive disorders (48.3% vs 24.0%, P < 0.001), lower room air saturation levels, albeit within the normal range (95.9% ± 2.9% vs. 96.9% ± 2.1%, P < 0.01) and higher rates of abnormal findings on chest x-rays (57.3% vs. 41.2%, P = 0.02). In a secondary analysis of the subgroup of 116 patients who were treated with Casirivimab/Imdevimab, there were no significant differences in the occurrence of severe outcome between those who were vaccinated and those who were not (45.8% vs. 54.3%, P = 0.49), nor between those who received the 3rd dose of vaccine and those who did not (12.5% and 15.2%, P > 0.99). In addition, no significant difference was observed in the occurrence of severe outcome between seronegative (IgG levels <1 U/ml) and seropositive (IgG levels ≥1 U/ml) patients (24.1% vs. 17.1%, P = 0.55) and no significant correlation was found between antibody titers and severe outcome (Spearman correlation 0.04, P = 0.73). Fifty patients had a severe outcome: 7 patients died within 45 days from their initial presentation and 48 had room air saturation <93% within 14 days from their initial presentation. Patients with a severe outcome were significantly older (68.7 ± 19.6 years vs.57.5 ± 20.9 years, P < 0.001) and higher rates of the severe outcome group had chronic kidney disease (24.0% vs. 8.1%, P < 0.001). Patients in the severe outcome group had significantly higher mean number of days from symptom onset (4.7 ± 3.2 vs. 3.7 ± 2.6, P = 0.01), significantly lower mean room air saturation values (94.4 ± 3.5 % vs. 96.9 ± 2.0%, P < 0.001), and significantly higher mean body temperature values (37.6 ± 0.9°C vs. 37.3 ± 0.7°C, P = 0.008). The neutrophil/lymphocytes ratio and the CRP levels were significantly higher for the severe outcome group (7.0 ± 7.6 vs. 4.9 ± 5.8, P = 0.03 and 73.7 ± 57.0 mg/dl vs. 36.3 ± 45.3 mg/dl, P < 0.001, respectively), along with abnormal chest- x ray findings at the presentation (77.8% vs. 39.6%, P < 0.001). (Table 1).Table 1Comparison of epidemiological and clinical characteristics of patients with and without severe disease outcome.P valueSevere disease outcome (n = 50)(N, %)No severe disease outcome(n = 309)(N, %)Characteristic<0.00168.7 ± 19.657.5 ± 20.9Age (mean±SD)0.5323 (46.0)167 (53.8)Sex (female)Vaccination status0.1826 (55.3)183 (66.3)At least one dose0.1223 (46.0)180 (58.3)≥2 doses0.536 (12.0)51 (16.5)3 doses>0.992 (4.2)10 (3.7)RecoveredRisk factors0.1117 (34.0)72 (23.3)Heart disease>0.998 (16.0)51 (16.6)Lung disease0.0519 (38.0)74 (23.9)Diabetes Mellitus0.00212 (24.0)25 (8.1)Chronic kidney disease0.6214 (28.0)100 (32.5)Immunosuppression0.443 (6.0)32 (10.4)Pregnancy0.010.404.7 ± 3.23.0 ± 2.93.7 ± 2.62.7 ± 2.6Days from symptoms onset (mean±SD)Days from positive PCR (mean±SD)0.6438 (84.4)266 (86.9)SymptomsVital signs (mean±SD)0.0691.0 ± 13.484.1 ± 16.7Pulse (bpm)<0.00194.4 ± 3.596.9 ± 2.0Saturation (%)0.46134.4 ± 21.3132.0 ± 20.8Systolic Blood Pressure (mmHg)0.4873.4 ± 13.174.8 ± 12.4Diastolic Blood Pressure (mmHg)0.00837.6 ± 0.937.3 ± 0.7Body temperature (Celsius)Laboratory results (mean±SD)0.239.5 ± 13.87.6 ± 9.2WBC (K/uL)0.037.0 ± 7.64.9 ± 5.8Neutrophil/lymphocytes ratio<0.00173.7 ± 57.036.3 ± 45.3CRP (mg/dL)<0.00135 (77.8)80 (39.6)CXR positive findings at presentation0.0124 (48.0)92 (29.8)Casirivimab/Imdevimab treatment (yes)Other treatment during hospital stay<0.00131 (62.0)24 (7.8)Anticoagulation<0.00116 (34.8)39 (12.5)Steroids<0.00113 (26.0)20 (6.5)Abx0.016.6 ± 6.73.7 ± 6.3LOS (days) (mean±SD) Open table in a new tab Independent predictors for severe outcome: factors with significance level of P < 0.15 in the univariable analysis (Table 1) and those considered as either risk or protective factors for severe disease outcome were inserted into a multi-regression analysis. Chronic kidney disease (aOR = 3.51 [95% CI: 1.34-9.20], P = 0.01), lower saturation (aOR = 0.7 [95% CI: 0.58–0.85], P < 0.01), and higher CRP levels (aOR = 1.01 [95% CI: 1.00 – 1.01], P = 0.008) emerged as independent risk factors of severe outcome. Positive immunization status was found to be an independent protective factor of severe outcome (aOR = 0.33 [95% CI: 0.14–0.77], P = 0.01). In contrast to previous report (18), Casirivimab/Imdevimab treatment was not found to be an independent protective factor for severe outcome (aOR = 1.54 [95% CI: 0.71–3.34], P = 0.26). Moreover, it had a significant association with severe disease outcome in the univariable analysis. Several factors may explain our observation. First, our sub-analysis revealed that patients who were treated with Casirivimab/Imdevimab had higher rates of immunosuppressive conditions, which had been reported to be associated with a higher likelihood of hospitalization following monoclonal antibody treatment ([7]Ganesh R. Philpot L.M. Bierle D.M. et al.Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019.J Infect Dis. 2021; 224: 1278-1286https://doi.org/10.1093/infdis/jiab377Google Scholar). Moreover, the COVID-19 mRNA vaccine, that was found to be an independent protective factor of severe outcome in our study, have lower effectiveness among immunocompromised patients compared to immunocompetent controls and the ability of the former to develop high neutralizing antibody titers and to be protected against severe COVID-19 outcomes were limited compared to the latter ([8]Mair M.J. Berger J.M. Berghoff A.S. Starzer A.M. Ortmayr G. Puhr H.C. et al.Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations.JAMA Oncol. 2021; : 1-8Google Scholar). These observations may partially explain the higher rates of severe outcome among patients who received Casirivimab/Imdevimab treatment, compared to those who were not, in our cohort. We, as others ([7]Ganesh R. Philpot L.M. Bierle D.M. et al.Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019.J Infect Dis. 2021; 224: 1278-1286https://doi.org/10.1093/infdis/jiab377Google Scholar), found chronic kidney disease to be an independent risk factor for severe disease outcome. The high prevalence of comorbidities in patients with chronic kidney disease, such as hypertension, cardiovascular disease, and diabetes mellitus, might contribute to the poorer outcomes among those COVID-19 patients. Greater disease severity was found to be associated with older age in a series of analyses ([9]Gao Y.D. et al.Risk factors for severe and critically Ill COVID-19 patients: a review.Allergy. 2021; 76 (Copenhagen)Web: 428-455Google Scholar). Although age was significantly higher in our severe disease outcome group in the univariable analysis, it was not an independent predictor for severe disease outcome in the multi-regression model, potentially due to co-factors such as chronic diseases. It should be borne in mind that our patients were selected by either older age or chronic disease and that our cohort already represents a high-risk group for severe disease outcome, and that our findings should be interpreted accordingly. A recent study found that Casrivimab/Imdevinab lost its antiviral activity against the Omicron variant, which quickly became the dominant variant ([10]Planas D. Saunders N. Maes P. Guivel-Benhassine F. Planchais C. Buchrieser J. et al.Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization.bioRxiv. 2021; (.12.14)472630https://doi.org/10.1101/2021.12.14.472630Google Scholar). These data, taken together with our results, raise some doubt about the benefit of Casrivimab/Imdevinab for treating new SARS-CoV-2 variants. To conclude, we found no added benefit to the administration of Casrivimab/Imdevinab monoclonal antibody therapy to a mostly vaccinated high-risk population with an early delta variant of SARS-COVID-19 infection. Additional studies of new variants in the vaccination era are needed to explore the effect of monoclonal antibody therapy on the severity of disease outcome. Members of the Tel Aviv Sourasky Medical Center Emergency Department study group: Nancy Bishouty, Pharmacy Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Ben Vaknin, Emergency department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ORCID ID: 0000-0002-0073-857X; Shira Haberman, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Malka Katz Shalhav, Emergency department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; David Zeltser, Emergency department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel None." @default.
• W4221046868 created "2022-04-03" @default.
• W4221046868 creator A5020106357 @default.
• W4221046868 creator A5037184053 @default.
• W4221046868 creator A5049417135 @default.
• W4221046868 creator A5074357921 @default.
• W4221046868 creator A5081471784 @default.
• W4221046868 creator A5088861580 @default.
• W4221046868 date "2022-06-01" @default.
• W4221046868 modified "2023-10-10" @default.
• W4221046868 title "Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection" @default.
• W4221046868 cites W3026764413 @default.
• W4221046868 cites W3098914336 @default.
• W4221046868 cites W3111431752 @default.
• W4221046868 cites W3184169211 @default.
• W4221046868 cites W3202209604 @default.
• W4221046868 cites W3206526516 @default.
• W4221046868 cites W3212357575 @default.
• W4221046868 cites W4206586084 @default.
• W4221046868 cites W4221072241 @default.
• W4221046868 cites W4225826670 @default.
• W4221046868 doi "https://doi.org/10.1016/j.ejim.2022.03.001" @default.
• W4221046868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35300887" @default.
• W4221046868 hasPublicationYear "2022" @default.
• W4221046868 type Work @default.
• W4221046868 citedByCount "0" @default.
• W4221046868 crossrefType "journal-article" @default.
• W4221046868 hasAuthorship W4221046868A5020106357 @default.
• W4221046868 hasAuthorship W4221046868A5037184053 @default.
• W4221046868 hasAuthorship W4221046868A5049417135 @default.
• W4221046868 hasAuthorship W4221046868A5074357921 @default.
• W4221046868 hasAuthorship W4221046868A5081471784 @default.
• W4221046868 hasAuthorship W4221046868A5088861580 @default.
• W4221046868 hasBestOaLocation W42210468682 @default.
• W4221046868 hasConcept C116675565 @default.
• W4221046868 hasConcept C126322002 @default.
• W4221046868 hasConcept C127413603 @default.
• W4221046868 hasConcept C144237770 @default.
• W4221046868 hasConcept C146978453 @default.
• W4221046868 hasConcept C148220186 @default.
• W4221046868 hasConcept C159047783 @default.
• W4221046868 hasConcept C177713679 @default.
• W4221046868 hasConcept C2778137277 @default.
• W4221046868 hasConcept C2779134260 @default.
• W4221046868 hasConcept C30036603 @default.
• W4221046868 hasConcept C3006700255 @default.
• W4221046868 hasConcept C3007834351 @default.
• W4221046868 hasConcept C3008058167 @default.
• W4221046868 hasConcept C33923547 @default.
• W4221046868 hasConcept C5072461 @default.
• W4221046868 hasConcept C524204448 @default.
• W4221046868 hasConcept C71924100 @default.
• W4221046868 hasConceptScore W4221046868C116675565 @default.
• W4221046868 hasConceptScore W4221046868C126322002 @default.
• W4221046868 hasConceptScore W4221046868C127413603 @default.
• W4221046868 hasConceptScore W4221046868C144237770 @default.
• W4221046868 hasConceptScore W4221046868C146978453 @default.
• W4221046868 hasConceptScore W4221046868C148220186 @default.
• W4221046868 hasConceptScore W4221046868C159047783 @default.
• W4221046868 hasConceptScore W4221046868C177713679 @default.
• W4221046868 hasConceptScore W4221046868C2778137277 @default.
• W4221046868 hasConceptScore W4221046868C2779134260 @default.
• W4221046868 hasConceptScore W4221046868C30036603 @default.
• W4221046868 hasConceptScore W4221046868C3006700255 @default.
• W4221046868 hasConceptScore W4221046868C3007834351 @default.
• W4221046868 hasConceptScore W4221046868C3008058167 @default.
• W4221046868 hasConceptScore W4221046868C33923547 @default.
• W4221046868 hasConceptScore W4221046868C5072461 @default.
• W4221046868 hasConceptScore W4221046868C524204448 @default.
• W4221046868 hasConceptScore W4221046868C71924100 @default.
• W4221046868 hasLocation W42210468681 @default.
• W4221046868 hasLocation W42210468682 @default.
• W4221046868 hasLocation W42210468683 @default.
• W4221046868 hasLocation W42210468684 @default.
• W4221046868 hasOpenAccess W4221046868 @default.
• W4221046868 hasPrimaryLocation W42210468681 @default.
• W4221046868 hasRelatedWork W3003901880 @default.
• W4221046868 hasRelatedWork W3004826915 @default.
• W4221046868 hasRelatedWork W3005417802 @default.
• W4221046868 hasRelatedWork W3007868867 @default.
• W4221046868 hasRelatedWork W3009669391 @default.
• W4221046868 hasRelatedWork W3020699490 @default.
• W4221046868 hasRelatedWork W3087206508 @default.
• W4221046868 hasRelatedWork W3099868929 @default.
• W4221046868 hasRelatedWork W3146699278 @default.
• W4221046868 hasRelatedWork W4206419631 @default.
• W4221046868 hasVolume "100" @default.
• W4221046868 isParatext "false" @default.
• W4221046868 isRetracted "false" @default.
• W4221046868 workType "article" @default.